Tag:
Epogen
Latest Headlines
Latest Headlines
Amgen pushes agenda for biosimilars on the FDA
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
Amgen founding CEO George Rathmann dies at 84
In the years after he took the helm of the company, Rathmann helped steer the development of Epogen and Neupogen. Only now does Amgen face rivals to its anemia franchise.
Affymax banks $50M milestone on ESA drug approval
Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.
Affymax approval breaks Amgen's long anemia monopoly
Now that FDA has approved a new, independent amenia drug competitor, will Amgen's versions plummet?
Affymax breaks Amgen's anemia drug monopoly with ESA approval
Amgen has finally lost control of the U.S. market for anemia drugs needed to treat dialysis patients.
Amgen's new meds beat estimates as anemia drugs slip
Amgen's ( $AMGN ) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen . New bone drugs Xgeva and Prolia beat analyst estimates for their first full
Affymax spikes after expert panel backs new anemia drug rival to Amgen
Shares of Affymax spiked more than 25% this morning as investors got a chance to show their enthusiasm for the big support FDA experts provided Wednesday afternoon for the biotech's experimental
Affymax investors bullish on FDA review of Amgen anemia drug rival
Facing an expert panel review for peginesatide on Wednesday, FDA staffers gave Affymax ( $AFFY ) a solid boost in confidence this morning with an agency review that backed the once-monthly anemia
Amgen strikes Epogen deals with DaVita, Fresenius
Amgen ( $AMGN ) is wheeling and dealing to protect sales of its anemia drug Epogen . The drugmaker has inked two new long-term supply contracts with dialysis providers, as it prepares for potential
Class-action securities suit goes forward against Amgen
A U.S. appeals court will let Amgen ( $AMGN ) investors keep their class-action status in a complaint accusing the company of failing to fully disclose potential safety problems with its anemia drugs
